StockNews.AI
ECOR
StockNews.AI
166 days

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

1. electroCore will report Q4 and full-year results on March 12, 2025. 2. A webcast will follow at 5:30 PM EDT for discussion and Q&A. 3. The company specializes in bioelectronic medicine with a focus on wellness. 4. Introducing non-invasive vagus nerve stimulation technology for medical applications. 5. Results could impact ECOR’s market perception and stock price.

Earnings
-7.61%Current Return
VS
-1.28%S&P 500
$15.3103/06 08:14 AM EDTEvent Start
$14.14503/07 02:47 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

upcoming earnings reports often drive investor sentiment; if results exceed expectations, past instances show significant price increases, like ECOR's Q3 2024 results.

How important is it?

earnings announcements can impact stock price significantly; if ECOR demonstrates growth, it could attract new investment.

Why Short Term?

earnings report will directly influence stock price in the near term; immediate trader reactions are expected.

Related Companies

NVCRSTIMAXGT
ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets. For more information, visit www.electrocore.com. Contact:ECOR Investor Relations(973) 302-9253Investors@electrocore.com

Related News